Accro Bioscience’s AC-101 tablets gain entry into NMPA’s Caring Plan‑Extension pilot, securing regulatory support for rare‑disease drug development in China
Executive summary: Accro Bioscience announced on September 14, 2026 that its AC‑101 tablets have been included in the NMPA CDE’s Caring Plan‑Extension pilot program for rare disease drug development. The pilot provides regulatory incentives that can reduce development costs and shorten timelines for AC‑101 in China, improving the product’s commercial prospects.
Who is involved: Accro Bioscience (Suzhou/NY) and the National Medical Products Administration’s Center for Drug Evaluation (CDE).
Likely next: Accro is expected to advance AC‑101 toward formal clinical trials and subsequently pursue a new drug application (NDA) under the pilot’s benefit framework.
On September 14, 2026, Accro Bioscience announced that its AC‑101 tablet formulation has been admitted to the National Medical Products Administration’s Center for Drug Evaluation (CDE) Caring Plan‑Extension pilot program, which encourages innovative drug development for rare diseases in China. The inclusion grants Accro access to potential incentives such as priority review pathways and reduced regulatory fees, aimed at accelerating development timelines. While the pilot does not guarantee approval, it signals regulatory willingness to support AC‑101’s progression toward clinical trials and eventual market access in China.
What's next — scenarios
Base: Pilot benefits realized, AC‑101 advances to Phase II (50%)
AC‑101 moves into mid‑stage testing in China with reduced fee burden.
- Completion of pilot‑program milestones by Q2 2027
- Positive pre‑toxicity data
- NMPA confirms continued pilot support
Upside: Accelerated approval leads to early market entry (30%)
AC‑101 receives conditional approval in China by late 2028, capturing first‑mover advantage in the rare‑disease niche.
- Positive interim efficacy data from pilot‑supported trial by Q4 2027
- NMPA grants priority review status
- Manufacturing scale‑up completed by mid‑2028
Downside: Pilot yields limited benefit, development stalls (20%)
AC‑101 faces delays or additional data requests, pushing potential launch beyond 2030.
- Pilot program concludes without extension of incentives by Q1 2028
- Identified safety signal requiring further study
- NMPA revises rare‑disease policy, removing AC‑101 eligibility
Timeline
- — Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development (PR Newswire)
- — Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo (PR Newswire)
Analysis — what this means
Sectors affected
- Rare disease therapeutics
- Biopharmaceutical
Historical parallels
- Accro Bioscience obtained NMPA IND clearance for AC‑201 in September 2026 (archive).
Key entities
Sources
- Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development — PR Newswire
- Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo — PR Newswire